{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T04:40:02Z","timestamp":1771389602231,"version":"3.50.1"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkish Journal of Gastroenterology"],"abstract":"<jats:p>Background: The course of hepatitis C disease has changed with the use of direct-acting antiviral drugs in the treatment of the disease.\n\nThe aim of this study was to evaluate the real-life efficacy and safety of the sofosbuvir\/ledipasvir drug regimen in the treatment of\n\npatients with genotype 1b.\n\nMethods: Treatment-naive or -experienced 49 genotypes 1b patients treated with sofosbuvir\/ledipasvir participated in the study.\n\nLaboratory and hepatitis C virus RNA values were evaluated at baseline, week 12, and week 24 of treatment (36th week for those who\n\nreceived 24 weeks of treatment).\n\nResults: The sustained virologic response rate was 100% in patients who completed treatment. At the end of the study, there was\n\na significant decrease in alanine transaminase, aspartate transaminase, gamma-glutamyl transferase, and alpha-fetoprotein levels\n\n(P = .000014, P = .000581, P = .000012, and P = .000821), respectively. Renal function tests (creatinine, estimated glomerular filtration\n\nrate) worsened (P = .003 and P = .007, respectively). Hepatocellular carcinoma (HCC) was developed in 2 patients during post-treatment\n\nfollow-up. In Kaplan\u2013Meier analysis, the probability of not developing HCC was 86.5% at 26 months.\n\nConclusion: The sofosbuvir\/ledipasvir combination is effective in treating genotype 1b chronic hepatitis C with high sustained virologic\n\nresponse rates. Because there are few drug interactions, it may be a suitable option for patients taking multiple medications or who\n\nare transplant recipients. Renal function should be monitored closely during and after treatment, as there is a risk of worsening renal\n\nfunction after treatment.<\/jats:p>","DOI":"10.5152\/tjg.2022.22029","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T10:57:51Z","timestamp":1648637871000},"page":"240-247","source":"Crossref","is-referenced-by-count":0,"title":["Real-Life Data on Sofosbuvir\/Ledipasvir in Patients with Chronic Viral Hepatitis C Genotype 1b: A Single-Center Experience"],"prefix":"10.5152","volume":"33","author":[{"given":"Arif Mansur","family":"Co\u015far","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Durak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3111","published-online":{"date-parts":[[2022,3,15]]},"container-title":["Turkish Journal of Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.turkjgastroenterol.org\/index.php\/tjg\/article\/download\/3853\/3515","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:31:24Z","timestamp":1771381884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.turkjgastroenterol.org\/index.php\/tjg\/article\/view\/3853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,15]]}},"URL":"https:\/\/doi.org\/10.5152\/tjg.2022.22029","relation":{},"ISSN":["2148-5607"],"issn-type":[{"value":"2148-5607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]}}}